Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease

BACKGROUND: Data on the performance of newer biologics in patients with fistulizing Crohn’s disease (CD) are limited. OBJECTIVE: Our study’s objective was to evaluate the response to ustekinumab (UST) and vedolizumab (VDZ) in patients with fistulizing CD. DESIGN: Retrospective cohort. METHODS: We us...

Descripción completa

Detalles Bibliográficos
Autores principales: Newman, Kira L., Johnson, Laura A., Stidham, Ryan W., Higgins, Peter D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989393/
https://www.ncbi.nlm.nih.gov/pubmed/36895282
http://dx.doi.org/10.1177/17562848221148254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989393/
https://www.ncbi.nlm.nih.gov/pubmed/36895282
http://dx.doi.org/10.1177/17562848221148254

Ejemplares similares